New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
16:13 EDTQGENQIAGEN announces three separate agreements to add biomarkers
QIAGEN announced three separate agreements that add multiple biomarkers to QIAGEN's development pipeline of diagnostics for Personalized Healthcare applications. QIAGEN intends to develop new diagnostics to guide treatment decisions, including companion diagnostics paired with medicines, based on these biomarkers. Most of these assays will be designed to run on the QIAsymphony RGQ modular laboratory workflow automation system as well as QIAGEN's next-generation sequencing workflows currently in development. QIAGEN has made a strategic equity investment in Drug Response Dx GmbH with the option to obtain worldwide rights to biomarkers for evaluation of rheumatoid arthritis patients to guide treatment with TNF-alpha inhibitors, which are widely prescribed for treatment of RA. QIAGEN has agreed to license exclusive worldwide rights from Insight Genetics for the RET, ROS1 and DEPDC1 biomarkers for use in non-small cell lung cancer, the most common form of lung cancer. QIAGEN Marseille has licensed exclusive worldwide rights to a biomarker for mutations of the HSP110 gene, which allows for identification of specific types of colorectal cancer, from InsermTransfert, the technology transfer arm of the French National Institute of Health and Medical Research.
News For QGEN From The Last 14 Days
Check below for free stories on QGEN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
16:14 EDTQGENQIAGEN sees Q3 adjusted EPS 26c-27c, consensus 27c
Sees Q3 adjusted net sales up 4%-5% CER.
16:13 EDTQGENQIAGEN reaffirms 2014 EPS outlook $1.07-1.09, consensus $1.09
Subscribe for More Information
16:12 EDTQGENQIAGEN announces new $100M share repurchase program
QIAGEN announced today the launch of its third $100M share repurchase program after completing its second $100M program in June. In the second repurchase program, approximately 4.5M shares were repurchased on the Frankfurt Stock Exchange.
16:12 EDTQGENQIAGEN reports Q2 adjusted EPS 26c, consensus 25c
Reports Q2 revenue $331.2M, consensus $330.8M.
July 28, 2014
05:36 EDTQGENQIAGEN, AstraZeneca announce collaboration
QIAGEN (QGEN) announced a collaboration agreement with AstraZeneca (AZN) for the co-development and commercialization of a liquid biopsy-based companion diagnostic to be paired with IRESSA, AstraZeneca's targeted therapy for non-small cell lung cancer, or NSCLC. The project builds on a master framework agreement signed by both companies in 2013 and aims to develop and market a novel QIAGEN companion diagnostic that analyzes plasma samples to assess EGFR mutation status in NSCLC patients. The assay will be designed to guide the treatment of NSCLC patients with Astra Zeneca's oral monotherapy anti-cancer treatment when tumor tissue is not available. QIAGEN already offers the therascreen EGFR RGQ PCR Kit as a tissue-based companion diagnostic for lung cancer patients, which was approved in the U.S. by the FDA in July 2013 and in China in May 2014. The companies will collaborate to create a new companion diagnostic for IRESSA based on liquid biopsy samples from NSCLC patients, rather than requiring invasive surgical collection of tissue samples. Data from several studies, including the IFUM Study presented at the "World Lung 2013" conference, provided evidence of the ability to assess the EGFR status of advanced lung cancer patients using blood / plasma samples. This breakthrough provides hope for patients for whom surgical biopsy is not an option by enabling them to have their EGFR mutation status assessed using a less invasive method.
July 24, 2014
16:17 EDTQGENQIAGEN acquires exclusive global license to the biomarker SF3B1
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use